Ocular Pathology Recommendations during COVID-19 from the American Association of Ophthalmic Oncologists and Pathologists (AAOOP)

• Published in: Ocular Oncology and Pathology 2020-04, Vol.6 (3), p.223-224
• Main Authors: Chévez-Barrios, Patricia, Milman, Tatyana, Grossniklaus, Hans E., Folberg, Robert, Salomão, Diva Regina, Gombos, Dan S.
• Format: Article
• Language: English
• Subjects: Letter to the Editor
• ISSN: 2296-4681; 2296-4657
• DOI: 10.1159/000507735

Submit the fresh specimen to Flow Cytometry (in RPMI or in a wet TELFA paper with a balanced salt solution) or Molecular (in a sterile container, dry) directly to the appropriate laboratory (not to frozen sections for the pathologist to divide) and place the other specimen immediately in formalin for Surgical Pathology. For up-to-date guidelines on CDC recommendations for laboratory COVID-19 biosafety please refer to the following website link: https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html Acknowledgement This document has been endorsed by the American Association of Ophthalmic Oncologists and Pathologists (AAOOP) Board of Directors. Available from: https://www.who.int/csr/resources/publications/biosafety/Biosafety7.pdf?ua=1 2 World Health Organization [Internet]: Laboratory biosafety guidance related to the novel coronavirus (2019 -nCoV) [ cited 2020 February 12 ]. https://www.who.int/docs/default-source/coronaviruse/laboratory-biosafety-novel-coronavirus-version-1-1.pdf?sfvrsn=912a9847_2 *Patricia Chévez-Barrios, MD, Chair in Ocular Pathology, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, 6565 Fannin St, M227, Houston, TX 77030 (USA), [e-mail]